对BCG用于重组疫苗的新用途
C K Stover1, V F de la Cruz, T R Fuerst
1MedImmune Incorporated, Gaithersburg, Maryland 20878.
Nature
|June 6, 1991
概括
细菌卡尔梅特 - 格林 (BCG) 疫苗可以被设计成表达外来抗原,在小鼠中诱导强大而持久的免疫反应. 这种方法增强了BCG作为多功能疫苗输送工具的潜力.
科学领域:
- 疫苗学 疫苗学 疫苗学
- 免疫学 免疫学 免疫学
- 微生物遗传学 微生物遗传学
背景情况:
- 巴西尔·卡尔梅特-盖林 (BCG) 是一种广泛使用的活体减弱疫苗.
- BCG作为一种潜在的疫苗载体,可以传递来自其他病原体的抗原.
- 开发有效的复合BCG菌株需要适当的表达系统.
研究的目的:
- 开发能够表达外来抗原的重组BCG菌株.
- 为了评估这些重组BCG菌株的免疫性.
主要方法:
- 使用BCG热冲击蛋白调节序列构建染色体外和整合表达载体.
- 将这些载体引入BCG以创建重组菌株.
- 在接种疫苗后的小鼠中评估幽默和细胞免疫反应.
主要成果:
- 成功开发出表达外来抗原的重组BCG菌株.
- 证明这些重组BCG菌株引起显著的幽默性免疫反应.
- 表明这些重组BCG菌株诱导长期的细胞免疫反应.
结论:
- 用特定载体设计的重组BCG菌株可以有效地表达外来抗原.
- 这些修改后的BCG疫苗在临床前模型中诱导了持久和全面的免疫保护.
- 作为一个灵活的平台,BCG有望开发针对各种传染病的新型疫苗.
相关概念视频
Vaccinations
Overview
Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...


